

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Becattini Cecilia	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : apixaban (2017-2018) - Daiichi Sankyo : edoxaban (2017-2018) - Boehringer-Ingelheim : dabigatran (2018) - Bayer Healthcare : rivaroxaban, aspirin (2018)
Bueno Hector	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : PCSK9 inhibitors (2017) - Novartis : Serelaxin, ACZ885, AHF Academy, (2017) - Ferrer Internacional : Trinomia (polypill) (2017) - Pfizer : Apixaban (2017-2018) - Bristol Myers Squibb : Apixaban (2017-2018) - Bayer : Aspirin, rivaroxaban (2017-2018) - MEDSCAPE-the heart.org : Inespecific (2017-2018) - Astra Zeneca : Ticagrelor (2017-2018) - Novartis : Canakinumab (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Bueno Hector	<p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Ticagrelor (2017) <p>E - RESEARCH FUNDING (PERSONAL).</p> <ul style="list-style-type: none"> - Novartis : LCZ696 - PROMISE trial / PERSPECTIVE trial / PREFER Study (2017) - Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2017) - Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2017) - BMS : CV013-011 - STANDUP-AHF trial (2017-2018) - Novartis : LCZ696 (PROMISE trial / PERSPECTIVE trial) (2018) - Astra Zeneca : Ticagrelor (EPICOR Study, THEMIS trial) (2018) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - VP elect. Spanish Society of Cardiology FAHA (2017) - Vice-president elect. Spanish Society of Cardiology (Will become VP in October 2019) FAHA (2018)
Geersing Geert-Jan	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : NOAC (2017-2018) - Bayer Healthcare : NOAC (2017-2018) - Roche Diagnostics : POC D-dimer testing (2017-2018) - Daiichi Sankyo : NOAC (2018) - Pfizer : NOAC (2018)
Harjola Veli-Pekka	Nothing to be declared (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Harjola Veli-Pekka	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Roche Diagnostics : Cardiac markers (2017) - Orion : Heart failure (2017) - Pfizer : Venous thromboembolism (2017) - Merck Sharp & Dohme : Venous thromboembolism (2017) - Bayer AG : Venous thromboembolism (2017) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott Laboratories : Point-of-care testing (2017)
Huisman Menno	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : anticoagulant (2017-2018) - Daiichi Sankyo : anticoagulant (2017-2018) - Pfizer : anticoagulant (2017-2018) - Bayer Healthcare : anticoagulant (2017-2018) - Bristol Myers Squibb : anticoagulant (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : anticoagulant (2017-2018) - Aspen : anticoagulant (2017-2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Huisman Menno	- Merck Sharp & Dohme : pulmonary hypertension (2017-2018)
Humbert Marc	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - GlaxoSmithKline : Ambrisentan, Epoprostenol (2017-2018) - Johnson & Johnson : Bosentan, Macitentan, Epoprostenol, Selexipag (2017-2018) - Merck Sharp & Dohme : Riociguat (2017-2018) - United Therapeutics : Treprostinil (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - GlaxoSmithKline : Ambrisentan, Epoprostenol (2017-2018) - Bayer : Iloprost, Riociguat (2017-2018)
Jennings Catriona Sian	Nothing to be declared (2017-2018)
Jimenez David	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer Healthcare : Anticoagulation (2017) - Daiichi Sankyo : Anticoagulation (2017-2018) - Pfizer : Anticoagulation (2017-2018) - Sanofi Aventis : Anticoagulation (2017-2018) - Bristol Myers Squibb : Anticoagulation (2017-2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Jimenez David	<ul style="list-style-type: none"> - Leo Pharma : Anticoagulation (2017-2018) - Bayer : Anticoagulation (2018) - Rovi : Anticoagulation (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Anticoagulation (2017) - Sanofi Aventis : Anticoagulation (2017) - Bayer Healthcare : Anticoagulation (2017) - Daiichi Sankyo : Diagnosis of pulmonary embolism (2018)
Konstantinides Stavros V	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Cardiovascular (2017-2018) - Pfizer : Cardiovascular (2017-2018) - Bayer Healthcare : Cardiovascular (2017-2018) - BTG Biocompatibles Group UK : Cardiovascular (2017-2018) - Merck Sharp & Dohme : Cardiovascular - Pulmonary hypertension (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Cardiovascular (2017-2018) - Bayer Healthcare : Cardiovascular (2017-2018) - Merck Sharp & Dohme : Cardiovascular (2017-2018) - Daiichi Sankyo : Cardiovascular - Anticoagulation (2017-2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Konstantinides Stavros V	- Actelion : Pulmonary hyoertension (2017-2018)
Kucher Nils	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bard : Devices (2017-2018) - EKOS Corp : Devices (2017-2018) - Optimed : Devices (2017-2018) - Pfizer : Drugs (2017-2018) - Sanofi Aventis : Drugs (2017-2018) - Bayer Healthcare : Drugs (2017-2018) - Bristol Myers Squibb : Drugs (2017-2018) <p>C - RECEIPT OF ROYALTIES FOR INTELLECTUAL PROPERTY.</p> <ul style="list-style-type: none"> - Optimed : Devices (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Swiss Heart Foundation : Devices (2017-2018) - EKOS Corp : Devices (2017-2018)
Lang Irene Marthe	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Kaneka : interventional devices (2017) - Medtronic : medical devices (2017)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Lang Irene Marthe

- Actelion : Pulmonary Hypertension medications (2017)
- Ferrer Internacional : Pulmonary Hypertension medications (2017)
- MSD : Pulmonary Hypertension medications (2017)
- AOP Orphan Pharmaceuticals : Pulmonary Hypertension medications (2017)
- Actelion : Pulmonary Hypertension drugs (2018)
- United Therapeutics : Pulmonary Hypertension drugs (2018)
- Ferrer Internacional : Pulmonary Hypertension drugs (2018)
- MSD : Pulmonary Hypertension drugs (2018)
- AOP Orphan Pharmaceuticals : Pulmonary Hypertension drugs (2018)

B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.

- Actelion : Pulmonary Hypertension medications (2017)
- AOP Orphan Pharmaceuticals : Pulmonary Hypertension medications (2017)
- Actelion : Pulmonary Hypertension drugs (2018)
- AOP Orphan Pharmaceuticals : Pulmonary Hypertension drugs (2018)

D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.

- Actelion : Pulmonary Hypertension medications (2017)
- AOP Orphan Pharmaceuticals : Pulmonary Hypertension medications (2017)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Lankeit Mareike	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Actelion : Macitentan, Selexipag; Pulmonary Hypertension (incl. PAH and CTEPH) (2017-2018) - Bristol Myers Squibb : Product: Apixaban; Therapeutic Area: Venous Thromboembolism (2017-2018) - Pfizer : Product: Apixaban; Therapeutic Area: Venous Thromboembolism / Pulmonary Hypertension (incl. PAH and CTEPH) (2017-2018) - Daiichi Sankyo : Product: Edoxaban; Therapeutic Area: Venous Thromboembolism (2017-2018) - MSD : Product: Riociguat; Pulmonary Hypertension (incl. PAH and CTEPH) (2017-2018) - Bayer : Product: Rivaroxaban; Therapeutic Area: Venous Thromboembolism (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - BRAHMS - Thermo Fisher Scientific : Laboratory biomarkers / assays (2018)
Lorusso Roberto	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Livanova : Bioprostheses (2017) - Livanova : Cardiac Valve Prostheses - Extracorporeal Circulation Technology (2018) - Medtronic Foundation : Cardiovascular Diseases and treatment (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Livanova : Cardiac Valve Prostheses - Extracorporeal Circulation Technology (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Mazzolai Lucia	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : anticoagulants (2017) - Sanofi Aventis : anticoagulants (2017) - Bayer : anticoagulants (2017-2018) - Amgen Inc : Lipid lowering (2018)
Meneveau Nicolas	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - BMS/Pfizer : Apixaban (2017-2018) - saint Jude medical : Consultant (OCT, FFR) (2017-2018) - Boehringer-Ingelheim : Dabigatran (2017-2018) - Terumo Inc : OFDI (2017-2018) - Bayer Healthcare : Rivaroxaban (2017-2018) - Edwards Life Sciences : TAVI (2017-2018) - Astra Zeneca : ticagrelor (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : DES (2017-2018) - Abbott Vascular : DES (2017-2018) - Medtronic : DES and TAVI (2017-2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Meneveau Nicolas	- St Jude Medical : OCT (2017-2018)
Meyer Guy	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Servier (my spouse is an employee of this company as occupational doctor) : my spouse is occupational doctor and is not involved in any therapeutic area for Servier (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer Healthcare : Anticoagulants (2017-2018) - Bristol Myers Squibb : Anticoagulants (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Leo Pharma : Anticoagulants (2017-2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - My spouse is employee of Servier, working as occupational medicine doctor for this compagny I personally received travel support from the following compagnies: Leo Pharma, BMS, Pfizer, bayer haelthcare and Daiichi Sankyo (2017)
Ni Ainle Fionnuala	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : apixaban (2017) - Daiichi Sankyo : edoxaban (2017) - Bayer : Rivaroxaban (2017) - Leo Pharma : tinzaparin (2017-2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Ni Ainle Fionnuala

B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.

- Bristol Myers Squibb : apixaban (2017)
- Sanofi Aventis : clexane (2017)
- Boehringer-Ingelheim : dabigatran (2017)
- Daiichi Sankyo : edoxaban (2017)
- Bayer : rivaroxaban (2017)
- Leo Pharma : Tinzaparin (2017)

D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.

- Actelion : congenital heart dx (2017-2018)
- Bayer : Rivaroxaban (2017-2018)
- BMS-Pfizer : Apixaban (2018)
- Sanofi Aventis : Clexane (2018)
- Leo Pharma : Tinzparin (2018)

2- Other Positions of Influence

2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.

- •Member of World Thrombosis Day International Steering Committee (<http://www.worldthrombosisday.org/>) (2018)

Prandoni Paolo

1- Financial Declaration

A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.

- Pfizer : THROMBOSIS - APIXABAN (2017-2018)
- Sanofi Aventis : THROMBOSIS - ENOXAPARIN (2017-2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Prandoni Paolo	- Bayer Pharma : THROMBOSIS - RIVAROXABAN (2017-2018)
Pruszczyk Piotr	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : anticoagulants (2017) - Pfizer : anticoagulants (2017) - Bayer Healthcare : anticoagulants (2017) - Pfizer : apixaban (2018) - Boehringer Ingelheim : dabigatran (2018) - Bayer Healthcare : rivaroxaban (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - National Institute for Health Research : CAD (2017)
Righini Marc	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - BioMérieux S.A : D-dimer testing (2017) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : Doacs (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Torbicki Adam	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : anticoagulants (2017) - Bayer Healthcare : pulmonary arterial hypertention - iloprost, riociguat, VTE - xarelto (2017) - Teva Pharmaceutical Industries : anti-cancer treatment (2017-2018) - Pfizer : anticoagulants - apixaban (2017-2018) - AOP Orphan Pharmaceuticals : pulmonary arterial hypertension (2017-2018) - Actelion : pulmonary arterial hypertension - macitentan, selexipag (2017-2018) - MSD : pulmonary hypertension - riociguat (2017-2018) - Berlin Chemie AG : heart failure (2018) - Bayer Healthcare : pulmonary arterial hypertention (2018) - United Therapeutics : pulmonary hypertension (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Actelion : pulmonary hypertension (2017-2018) - Bayer Healthcare : pulmonary hypertension (2017-2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Chairperson of Pulmonary Hypertension Foundation which receives donations from various institutions, including pharmaceutical and medical equipment companies for its statute activities (research, education and support of clinical activities of centers dedicated to pulmonary hypertension). The Chairperson does not receive honoraria or any other direct or indirect form of payment from the Foundation or its supporters. (2017-2018)
---------------	---

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Van Belle Eric	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : FFR (2017-2018) - Philips : FFR/iFR (2017-2018)
Zamorano Gomez Jose Luis	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : afib (2017) - Pfizer : Afib (2017) - Daiichi Sankyo : Anticoagulation Afib (2018) - Amgen : lipids (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Abdelghany Mansour	Nothing to be declared (2018)
Aboyans Victor	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : Antithrombotic therapy (2018) - BMS/Pfizer Alliance : Antithrombotic therapy (2018) - NovoNordisk : Diabetes (2018) - Novartis : Heart Failure (2018) - Amgen : Lipid lowering therapy (2018) - Sanofi Aventis : PAD (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer Healthcare : PAD (2018)
Ageno Walter	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Apixaban (2018) - Boehringer-Ingelheim : Dabigatran (2018) - Daiichi Sankyo : Edoxaban (2018) - Bayer Healthcare : Rivaroxaban (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Ageno Walter	<p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY. - Bayer Healthcare : rivaroxaban (2018)</p>
Agewall Stefan	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Boehringer-Ingelheim : Antidiabetic treatment (2018)</p>
Almeida Ana Maria G	<p>Nothing to be declared (2018)</p>
Andreotti Felicita	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Pfizer : apixaban (2018) - BMS : apixaban (2018) - Boehringer Ingelheim : dabigatran (2018) - Amgen : dyslipidaemia (2018) - Daiichi Sankyo : edoxaban (2018) - Bayer Schering Pharma : rivaroxaban (2018)</p>
Angoulvant Denis	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Servier : Coronary Heart Disease (2018)</p>

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Angoulvant Denis	<ul style="list-style-type: none"> - Novartis : Heart Failure and Atherosclerosis (2018) - Amgen : Lipids and Atherosclerosis (2018) - Sanofi Aventis : Lipids and Atherosclerosis (2018) - MSD : Lipids and Atherosclerosis (2018) - Boehringer-Ingelheim : Thrombosis (2018) - Pfizer : Thrombosis (2018) - BMS : Thrombosis (2018) - Bayer : Thrombosis and Atherosclerosis (2018) - Astra Zeneca : Thrombosis, Diabetes (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - BMS/Pfizer : Apixaban (2018) - Amgen : Evolocumab (2018) - Bayer : Rivaroxaban (2018) - Novartis : Valsartan Sacubitril (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Biotronik : Interventional cardiology (2018) - Abbott Vascular : Interventional cardiology (2018)
Asfalou Iliyasse	Nothing to be declared (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Aujesky Drahomir	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulants - rivaroxaban (2018)
Barbato Emanuele	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : Speaker fees (2018) - Abbott Vascular : Speaker fees (2018)
Bauersachs Johann	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : ACS, Afib (2018) - Orion : Acute Heart Failure (2018) - Abiomed : acute heart failure (2018) - Boehringer-Ingelheim : Afib, Diabetes mellitus, Heart Failure (2018) - Bayer : Afib, heart failure (2018) - Bristol Myers Squibb : Afib, heart failure (2018) - Merck Sharp & Dohme : CAD, Hypercholesterolemia, heart failure (2018) - Abbott : Heart Failure (2018) - Medtronic : Heart Failure (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Bauersachs Johann	<ul style="list-style-type: none"> - Servier : Heart Failure (2018) - CVRx : Heart Failure (2018) - Pfizer : Heart Failure, Afib (2018) - Biotronik : Heart Failure, CAD (2018) - Vifor International : heart failure, hyperkalemia (2018) - Astrazeneca : heart failure, hyperkalemia (2018) - Novartis : Hypertension, Heart Failure (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Zoll Medical : Arrhythmia (2018) - Medtronic : CAD, heart failure (2018) - Abiomed : cardiogenic shock (2018) - Vifor International : Heart failure (2018) - CVRx : Heart Failure (2018) - Bayer : heart failure, CAD (2018)
Baumbach Andreas	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Drugs (2018) - Abbott Vascular : Stents (2018) - Microport : Stents (2018) - Sinomed : Stents (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Baumbach Andreas	<p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <p>- Abbott Vascular : Stents (2018)</p>
Beygui Farzin	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <p>- Biosensors : Interventional cardiology devices (2018)</p> <p>- Boston Scientific : Interventional cardiology devices (2018)</p> <p>- Medtronic : Interventional cardiology devices (2018)</p> <p>- St Jude Medical : Interventional cardiology technology (2018)</p> <p>- Acist : Interventional cardiology technology (2018)</p> <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <p>- Congress Fee by BristolMyersSquibb (2018)</p>
Bosevski Marijan	<p>Nothing to be declared (2018)</p>
Bulatovic Nebojsa	<p>Nothing to be declared (2018)</p>
Bytyci Ibadete	<p>Nothing to be declared (2018)</p>
Carlsen Joern	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <p>- Actelion : Pulmonary hypertension (2018)</p>

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Carlsen Joern	<p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Actelion : Pulmonary hypertension (2018)
De Carlo Marco	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : alirocumab (2018) - Boehringer-Ingelheim : dabigatran (2018) - Volcano : iFR (2018) - Bayer AG : rivaroxaban (2018)
Delcroix Marion	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Actelion : pulmonary hypertension (2018) - MSD : pulmonary hypertension (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Actelion : pulmonary hypertension (2018)
Delgado Victoria	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott Vascular : Mitraclip (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Delgado Victoria	<p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - GE Healthcare : Echocardiography (2018) - Edwards Lifesciences : Transcatheter valve interventions (2018)
Diaconu Nadejda	Nothing to be declared (2018)
Ereminiene Egle	Nothing to be declared (2018)
Escribano Subias Maria Pilar	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Actelion : Pulmonary hypertension (2018) - GlaxoSmithKline : Pulmonary hypertension (2018) - Ferrer Internacional : Pulmonary hypertension (2018) - Merck Sharp & Dohme : pulmonary hypertension (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Actelion : pulmonary hypertension (2018) - Merck Sharp & Dohme : pulmonary hypertension (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Actelion : pulmonary hypertension (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Ferreira Daniel	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Artificial Intelligence - Advisory Board (2018) - Bayer Portugal : Rivaroxaban; Anticoagulation - Advisory Board (2018) - Astra Zeneca : Ticagrelor; Antithrombotic Treatment - Advisory Board (2018) <p>2- Other Positions of Influence</p> <p>2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - Consultant Cardiologist in Hospital da Luz Lisboa (2018) <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - Vice President for the Portuguese Society of Cardiology (2018)
Fitzsimons Donna	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Medscape : Heart failure (2018)
Gaine Sean	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Menarini : COPD (2018) - Actelion : Pulmonary Hypertension (2018) - United Therapeutics : Pulmonary Hypertension (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Galie Nazzareno	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : Pulmonary Hypertension (2018) - Actelion : Pulmonary hypertension (2018) - Bayer Healthcare : Pulmonary Hypertension (2018) - Merck Sharp & Dohme : Pulmonary Hypertension (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Actelion : Pulmonary Hypertension (2018) - Bayer Healthcare : Pulmonary Hypertension (2018)
Giannakoulas George	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Menarini : Chronic coronary artery disease (2018) - Astra Zeneca : Diabetes mellitus (2018) - Novartis : Heart Failure (2018) - Roche Diagnostics : Heart Failure (2018) - GenesisPharma : Heart Failure (2018) - Servier : Heart Failure-Chronic Coronary Artery Disease (2018) - Mylan : Hyperlidaemia (2018) - Sanofi Aventis : Hyperlipidemia (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Giannakoulas George	<ul style="list-style-type: none"> - Vianex : Hyperlipidemia (2018) - MSD : Hyperlipidemia-Pulmonary Hypertension (2018) - Actelion : Pulmonary Hypertension (2018) - GlaxoSmithKline : Pulmonary Hypertension (2018) - Lilly : Pulmonary Hypertension (2018) - Galenica Greece : Pulmonary Hypertension (2018) - Boehringer-Ingelheim : Thromboembolic Disease (2018) - Elpen Pharmaceuticals : Thromboembolic Disease (2018) - Pfizer : Thromboembolic Disease - Heart Failure (2018)
Gibbs Simon	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : Pulmonary hypertension (2018) - Actelion : Pulmonary hypertension (2018) - Merck Sharp & Dohme : Pulmonary hypertension (2018) - GSK : Pulmonary hypertension (2018) - Bellerophon : Pulmonary hypertension (2018) - Arena : Pulmonary hypertension (2018) - Complexa : Pulmonary hypertension (2018) - Acceleron : Pulmonary hypertension (2018) - Bayer Healthcare : Riociguat (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Gibbs Simon	<p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - I was a Trustee of the Preventive Cardiology Trust and also Breathing PLC, both of which are registered charities. (2018)</p>
Goldhaber Samuel Z	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : Pharma (2018) - Boehringer-Ingelheim : Pharma (2018) - Daiichi Sankyo : Pharma (2018) - BMS : Pharma (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Thrombosis Research Institute : Charitable Foundation (2018) - Bayer : Pharma (2018) - Boehringer-Ingelheim : Pharma (2018) - Daiichi Sankyo : Pharma (2018) - Janssen-Cilag : Pharma (2018) - BMS : Pharma (2018) - BTG : Pharma (2018) - NHLBI : USA Government (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Goldhaber Samuel Z	<p>2- Other Positions of Influence</p> <p>2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring. - Brigham and Women's Hospital (2018)</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology. - American Heart Association (2018)</p>
Gopalan Deepa	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Bayer AG : Imaging of Pulmonary Hypertension (2018)</p>
Habib Gilbert	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Pfizer : Amyloidosis (2018) - Genzyme : Fabry disease (2018) - Abbott : Mitraclip (2018) - Actelion : pulmonary hypertension (2018)</p>
Halvorsen Sigrun	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Bristol Myers Squibb : Antithrombotic treatment (2018) - Astra Zeneca : Anti-thrombotic treatment (2018) - Boehringer-Ingelheim : Anti-thrombotic treatment (2018)</p>

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Halvorsen Sigrun	<ul style="list-style-type: none"> - Pfizer : Anti-thrombotic treatment (2018) - Bayer AS : Anti-thrombotic treatment (2018) - Sanofi Aventis : Cholesterol lowering treatment (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Heart failure (2018)
Hammoudi Naima	Nothing to be declared (2018)
Hayrapetyan Hamlet	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Berlin-Chemie Menarini : Arterial Hypertension (2018) - Servier : Arterial Hypertension, Coronary Heart Diseases (2018) - Novartis : Heart Failure (2018)
Huijnen Steve	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Heart failure (2018)
Hutyra Martin	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Adempas (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Hutyra Martin	<ul style="list-style-type: none"> - Astra Zeneca : Brilique (2018) - Servier : Cosyrel, Prestarium (2018) - AOP Orphan Pharmaceuticals : Remodulin (2018) - Actelion : Uptravi, Veletri, Opsumit (2018)
Ibanez Borja	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : behavioral intervention (no drug) (2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - My center (CNIC) is a non-profit organization that receives royalties for the sales of a polypill (trinomia) which is constituted by aspirin-ramipril-simvastatin. I have NO direct interest (no personal benefits). (2018)
Ibrahimov Firdovsi	Nothing to be declared (2018)
Jaaskelainen Pertti	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : cardiovascular (2018) - Boehringer-Ingelheim : cardiovascular (2018) - Pfizer : cardiovascular (2018) - Merck Sharp & Dohme : cardiovascular (2018) - Actelion : PAH (2018) - Astra Zeneca : tikagrelor (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Jaaskelainen Pertti	<p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : heart failure (2018) <p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - ALL AREAS OF CARDIOLOGY - Ownership of shares of Orion Pharma, value of shares <1,000 eur (2018) <p>2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - I am a part time employee in Satucon Inc. (a company providing health care services) as a consultant cardiologist (=interpretation of ECGs) in clinical pharmaceutical trials in the field of psychiatry sponsored by various pharmaceutical companies (e.g. Servier/Parexel). The salary is < 10k€/year. - my father (M.D., psychiatrist) is a part time employee in Satucon Inc. Besides working as a psychiatrist, he is involved as an investigator in various clinical trials sponsored by pharmaceutical companies (Servier/Parexel, Lundbeck/Icon) in the field of psychiatry. The estimated payment to Satucon Inc. from pharmaceutical companies is 50-100 k €/year. - my mother (registered nurse) is a part time employee in Satucon Inc.. She is involved as a research nurse in the abovementioned clinical trials sponsored by pharmaceutical companies. (2018) <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - My institution (Heart Center, Kuopio University Hospital) is involved in a number of past and ongoing healthcare industry sponsored scientific studies, in which I am not directly involved as an investigator (except for PARADISE-MI study sponsored by Novartis). (2018)
Jenkins David	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Actelion : CTEPH (2018) - Bayer AG : CTEPH (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : Pulmonary hypertension drug trial (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Katus Hugo	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Anticoagulants (2018) - Bayer Vital : Anticoagulants (2018) - Astrazeneca : Antiplatelet (2018) - Roche Diagnosticsker : Biomar (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Roche Diagnosticsarker : Biomarker (2018) - Daiichi Sankyo : Xarelto (2018) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - President of the German Society of Cardiology (2018)
Kaymaz Cihangir	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Actelion : pulmonary hypertension (2018) - Bayer : venous thromboembolism, anticoagulants (2018) - Pfizer : venous thromboembolism, anticoagulants (2018)
Kjellstrom Barbro	<p>Nothing to be declared (2018)</p>

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Lainscak Mitja	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Atrial fibrillation (2018) - Novartis : Heart Failure (2018) - Vifor International : Heart Failure (2018) - Krka Pharma : Hypertension (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Roche Diagnostics : Heart Failure (2018)
Lancellotti Patrizio	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Servier : Heart failure (2018) - Abbott : MitraClip (2018) - Medtronic : TAVI (2018)
Le Gal Gregoire	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Portola Pharmaceuticals : Betrixaban (2018) - Pfizer : Dalteparin (2018) - Sanofi Aventis : Enoxaparine (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Le Gal Gregoire	<ul style="list-style-type: none"> - Aspen : Nadroparin (2018) - Bayer : Rivaroxaban (2018)
Lee Geraldine	Nothing to be declared (2018)
Maca Aija	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulants (2018) - Boehringer-Ingelheim : Anticoagulants (2018)
Mascherbauer Julia	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : Cardiac Amyloidosis (2018) - Daiichi Sankyo : NOAC (2018) - Boston Scientific : Valve Interventions (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : Cardiac Amyloidosis (2018)
Mellemkjaer Soren	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : Pulmonary Hypertension (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Mellemkjaer Soren	- Actelion : Pulmonary Hypertension (2018)
Messas Emmanuel	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : RIVAROVXABAN (2018) - Novartis : TASIGNA (2018) <p>C - RECEIPT OF ROYALTIES FOR INTELLECTUAL PROPERTY.</p> <ul style="list-style-type: none"> - Cardiawave : uktrason therapeutic (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - MSD : anti diabetic (2018)
Michaloliakos Ioannis	Nothing to be declared (2018)
Moiseeva Olga	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : Pulmonary hypertension (2018) - Actelion : Pulmonary hypertension (2018) - Bayer AG : Pulmonary hypertension (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : Pulmonary hypertension (2018) - Actelion : Pulmonary hypertension (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Morais Joao	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer / BMS : apixabano (anticoagulants) (2018) - Amgen Inc : evolocumab (lipids) (2018) - Bayer AG : rivaroxabano (anticoagulants) (2018) - Novartis : sacubitril (heart failure) (2018) - Servier : sacubitril (heart failure), ivabradina (ischemic heart disease) (2018) - Astra Zeneca : Ticagrelor (antiplatelets); dapaglifozina (diabetes) (2018) - Ferrer Internacional : trinomina (arteriosclerose) (2018)
Obradovic Slobodan	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : Honoraria for lectures and advisory board for apixaban and sildenafil (2018) - Boehringer-Ingelheim : Honoraria for lectures and advisory board for dabigatran and empagliflosine (2018) - Astra Zeneca : Honoraria for lectures and advisory board for ticagrelor (2018) - Servier : Honoraria for lectures and advisory board for trimetazidine (2018) - Bayer Healthcare : Honoraria fro lectures and advisory board for rivaroxaban and aspirin (2018) - Berlin Chemie AG : Lectures and advisory board for nebivolol and olmesartan (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Parkhomenko Alexander	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - BHFZ : corvitin (2018) - Sanofi Aventis : enoxaparin (2018) - Servier : preductal (2018) - Bayer Healthcare : rivaroxaban (2018) - Astra Zeneca : ticagrelor (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - European Research Foundation FP7 : European Research Foundation FP7 grant 2014-2018 (2018)
Pepke-Zaba Joanna	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Actelion : macitentan, selexipag, veletri (2018) - Merck Sharp & Dohme : riociguat (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Actelion : macitentan, selexipag, veletri (2018) - Merck Sharp & Dohme : riociguat (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Actelion : macitentan, selexipag, veletri (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Pepke-Zaba Joanna	<ul style="list-style-type: none"> - Merck Sharp & Dohme : riociguat (2018) E - RESEARCH FUNDING (PERSONAL). <ul style="list-style-type: none"> - Actelion : macitentan, selexipag, veletri (2018) - Merck Sharp & Dohme : riociguat (2018)
Petersen Steffen Erhard	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software (2018) - Servier : Heart failure (2018) <p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - IMAGING - I have option for shares for Circle Cardiovascular Imaging Inc. (2018)
Petris Antoniu Octavian	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novo Nordisk Farma SRL : antidiabetes (2018) - Pfizer : Apixaban Eliquis (2018) - Servier : Corlentor Angina (2018) - Boehringer-Ingelheim : Dabigatran PRADAXA (2018) - Societatea Romana de Cardiologie : Electrocardiography for ICU nurses (2018) - Novart Pharma Services Romania SRL : Entresto (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Petris Antoniu Octavian	<ul style="list-style-type: none"> - S.C. Berlin-Chimie Menarini SRL : Hypertension (2018) - Sc Alfasigma SRL : ischemia (2018) - Servier : Prestarium, Triplixam, Noliprel, Noliterax Hypertension (2018) - Bayer SRL : Rivaroxaban anticoagulation (2018) - Astra Zeneca : Ticagrelor Brilique (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : International Registry to assess mEdical Practice with lOngitudinal obseRvation for Treatment of Heart Failure REPORT-HF (2018)
Petronio Anna Sonia	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : Percutaneous Aortic and Mitral treatment (2018) - Medtronic : Percutaneous Aortic and mitral treatment (2018) - Abbott : Percutaneous Mitral treatment (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : TAVI research (2018)
Piepoli Massimo Francesco	Nothing to be declared (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Polonetsky Oleg	1- Financial Declaration A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Medtronic : Coronary and valve interventions (2018)
Price Susanna	2- Other Positions of Influence 2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring. - Employed full-time by the UK National Health Service as a clinical consultant in intensive care and cardiology at the Royal Brompton Hospital (2018)
Radsel Peter	Nothing to be declared (2018)
Reinmets Julia	Nothing to be declared (2018)
Roffi Marco	1- Financial Declaration D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY. - Boston Scientific : Stents (2018) - Medtronic : Stents (2018) - Biotronik : stents (2018) - Terumo Inc : stents (2018) - Abbott Vascular : stents (2018)
Salvi Aldo	Nothing to be declared (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Sanchez Olivier	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : AngioJet (2018) - BMS : apixaban (2018) - BTG : Ekos (2018) - Sanofi Aventis : enoxaparin (2018) - MSD : riociguat (2018) - Bayer : rivaroxaban (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - MSD : riociguat (2018)
Shlyakhto Evgeny	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Krka Pharma : Arterial Hypertension (2018) - Novartis : Arterial Hypertension, Heart Failure (2018) - Merck Sharp & Dohme : Atherosclerosis (2018) - Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2018) - Pfizer : General Cardiology (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Simkova Iveta	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Actelion : bosentan, macitentan (2018) - Merck Sharp & Dohme : riociguat (2018) - Pfizer : sildenafil (2018) - AOP Orphan Pharmaceuticals : treprostinil (2018)
Simpson Iain A	<p>Nothing to be declared (2018)</p>
Skoric Bosko	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Teva Pharmaceutical Industries : Eprizet (rosuvastatin/ezetimibe) (2018) - Boehringer-Ingelheim : Pradaxa (2018) - Berlin Chemie AG : ranolazine (2018) - Bayer AG : Xarelto (2018)
Sobkowicz Bozena	<p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - Provincial consultant in the field of cardiology (Podlasie Province) (2018)
Stortecky Stefan	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : Transcatheter heart valves (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Stortecky Stefan	<ul style="list-style-type: none"> - Edwards Lifesciences : Transcatheter heart valves (2018) - Medtronic : Transcatheter heart valves (2018) - Fumedica : Transcatheter heart valves (2018)
Sugraliyev Akhmetzhan	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Takeda Pharmaceuticals : Arterial Hypertention (2018)
Thielmann Matthias	<p>Nothing to be declared (2018)</p>
Tokmakova Mariya	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : ACS (2018) - Bayer : Anticoagulation (2018) - Boehringer-Ingelheim : Anticoagulation (2018) - Pfizer : Anticoagulation (2018) - Amgen : Dyslipidemia (2018) - Novartis : Heart failure (2018) - Merck Sharp & Dohme : Hypertension (2018) - Berlin Chemie AG : Hypertension, HF (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Vizza Carmine Dario	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Actelion : pulmonary arterial hypertension (2018) - Bayer : pulmonary hypertension (2018) - GlaxoSmithKline : pulmonary hypertension (2018) - Ferrer Internacional : pulmonary hypertension (2018) - Merck Sharp & Dohme : pulmonary hypertension (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Actelion : pulmonary hypertension (2018) - United Therapeutics : pulmonary hypertension (2018)
Vonk Noordegraaf Antonie	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Actelion : pulmonary hypertensin (2018) - MSD : pulmonary hypertension (2018)
Wikstrom Bernt Gerhard	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Actelion : PAH therapies (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Wikstrom Bernt Gerhard	<p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Orion : Heart failure (2018) - Vifor International : heart failure (2018) - Shire HGT : heart hypertrophy (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Actelion : CTEPH (2018) <p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Education - lecturer for health care personel in many European. countries (2018)
Xuereb Robert G	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Entresto - Heart Failure (2018)
Zavatta Marco	<p>Nothing to be declared (2018)</p>
Zima Endre	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Innomed Hun LTd : CPR, AED, Defibrillation (2018) - Boston Scientific : CRM (2018)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Zima Endre	<ul style="list-style-type: none"> - Medtronic : CRM (2018) - Biotronik : CRM (2018) - Zoll Medical : Defibrillation, CPR, TTM (2018) - Orion : Inotrope therapy (2018) - Pfizer : NOACs (2018) - Merck Sharp & Dohme : NOACs (2018) - Replant : TTM (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : Hyperlipidemia (2017) - Novartis : Hypertension (2017) - Boehringer-Ingelheim : Oral anticoagulation (2017) - Bayer Healthcare : Oral anticoagulation (2017) - Pfizer/BMS alliance : Oral anticoagulation (2017) - Bayer : Antithrombotic therapy (2018) - BMS/Pfizer Alliance : Antithrombotic therapy (2018) - NovoNordisk : Diabetes (2018) - Novartis : Heart Failure (2018) - Amgen : Lipid lowering therapy (2018) - Sanofi Aventis : PAD (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer Healthcare : PAD (2018)
Baigent Colin	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Empagliflozin (2017-2018) - Novartis : Sacubitril (2017-2018) - Pfizer : Sirolimus (2017-2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Lecture fees representing 2000 euros for 2017. (2017) - Roche Diagnostics : Lecture fees representing 800 euros for 2017. (2017) - Bayer Healthcare : Speaker Fees for antiplatelet therapy. This represented 2000 euros in total for 2017. (2017) - Servier : SPEAKER FEES OF 1000 EUROS IN 2017 (2017) - Bristol Myers Squibb : Apixaban (2018) - Astra Zeneca : TICAGRELOR (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : ACADEMIC RESEARCH DONATION TO THE ACTION FOUNDATION (www.action-fonds.org) (2017) - Bayer AG : ACADEMIC RESEARCH FUNDINGS (ADRIFT TRIALS) to the action study group (www.action-fonds.org) (2017) - Astra Zeneca : ACADEMIC RESEARCH FUNDINGS (ALPHEUS TRIAL) to the action study group (www.action-fonds.org) (2017) - Medtronic : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017) - Bristol Myers Squibb and Pfizer : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017) - Bristol Myers Squibb : apixaban (2018) - Medtronic : COREVALVE (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Delgado Victoria	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott Vascular : Mitraclip (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : pacemakers (2017) - Medtronic : pacemakers (2017) - Biotronik : pacemakers (2017) - Edwards Lifesciences : valves (2017) - GE Healthcare : Echocardiography (2018) - Edwards Lifesciences : Transcatheter valve interventions (2018)
Fitzsimons Donna	<p>Nothing to be declared (2017)</p> <p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Medscape : Heart failure (2018)
Gale Christopher Peter	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astrazeneca : ACS, heart failure (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Gale Christopher Peter	<ul style="list-style-type: none"> - Vifor Pharma : Heart failure (2017) - Novartis : heart failure, CVD (2017) - Astra Zeneca : ACS (2018) - Novartis : coronary artery disease (2018) - Bayer : coronary artery disease, AF (2018) - Vifor International : heart failure (2018) - Menarini : ischaemic heart disease (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Apixiban, AF (2018)
Grobbee Diederick E	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : advisory board (2018) - Esperion : Steering ctt (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Esperion : clinical trial lipids (2018) <p>2- Other Positions of Influence</p> <p>2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - chief scientific officer Julius Clinical Research Ltd (2017) - chief scientific officer Julius Clinical Research Ltd (part-time) (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Halvorsen Sigrun	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Antithrombotic treatment (2017-2018) - Astra Zeneca : Anti-thrombotic treatment (2017-2018) - Boehringer-Ingelheim : Anti-thrombotic treatment (2017-2018) - Pfizer : Anti-thrombotic treatment (2017-2018) - Bayer AS : Anti-thrombotic treatment (2017-2018) - Sanofi Aventis : Cholesterol lowering treatment (2017-2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Heart failure (2017-2018)
Hindricks Gerhard	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : Pacemaker, Ablation (2017-2018) - Biosense Webster : Pacemaker, Ablation (2017-2018) - Biotronik : Pacemaker, catheter (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott, Biotronik, Medtronic, Boston Scientific : Electrophysiology, arrhythmias (2017) - Biosense Webster : Electrophysiology, arrhythmias (2018) - Abbott : Electrophysiology, arrhythmias (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Hindricks Gerhard	<p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the Helios Hospital Group. (2017-2018)
lung Bernard	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Heart failure drugs (2017) - Boehringer Ingelheim : Anticoagulants (2017-2018) - Edwards Lifesciences : Heart valve prostheses (2017-2018)
Juni Peter	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Anti-platelet Therapy (2017-2018) - Biotronik : Drug-eluting stents (2017-2018) - Biosensors International Group : Drug-eluting stents (2017-2018) - The Medicines Company : Thrombin inhibitors (2017-2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Peter Jüni has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company. (2017) - Peter Jüni serves as unpaid member of the steering group of trials funded by St. Jude Medical. (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Katus Hugo	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Lixiana_NOAK (2017) - Astra Zeneca : Ticagrelor (2017) - Bayer Vital : Xarelto-NOAK (2017) - Daiichi Sankyo : Anticoagulants (2018) - Bayer Vital : Anticoagulants (2018) - Astrazeneca : Antiplatelet (2018) - Roche Diagnosticsker : Biomar (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - St Jude Medical : Biobank (2017) - Philips : MRT (2017) - Roche Diagnosticsarker : Biomarker (2018) - Daiichi Sankyo : Xarelto (2018) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - President of the German Society of Cardiology (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Landmesser Ulf	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : Advisory Board fees (2017-2018) - Medicines Company : Advisory Board fees (2017-2018) - Amgen : Speaker fees (2017-2018) - Sanofi Aventis : Speaker fees (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer AG : Research Grant (2017-2018)
Leclercq Christophe	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Livanova : devices (2017) - Abbott : devices (2017-2018) - Boston Scientific : devices (2017-2018) - Medtronic : devices (2017-2018) - Biotronik : devices (2017-2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Biotronik : devices (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Leclercq Christophe	<p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Biotronik : devices (2017)
Lettino Maddalena	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Antithrombotic agents, anticoagulants (2017) - Bristol Myers Squibb : Antithrombotic agents, anticoagulants (2017) - Amgen : Lipid lowering drugs (2017) - Pfizer : Anticoagulants (2017-2018) - Bayer Healthcare : Antithrombotic agents, anticoagulants (2017-2018) - Sanofi Aventis : Antithrombotic agents, anticoagulants, lipid lowering drugs (2017-2018) - Astra Zeneca : Antithrombotic agents, statins (2017-2018) - Daiichi Sankyo : Anticoagulants (2018)
Lewis Basil S	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : Antithrombotics (2017-2018) - Merck Sharp & Dohme : Heart failure (2017-2018) - Astra Zeneca : Diabetes (2018) - CSL Behring : Lipidology, Secondary prevention (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Lewis Basil S	<p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Heart failure (2017) - Pfizer : Lipidology (2017) - Astrazeneca : Antithrombotics (2017-2018) - Astra Zeneca : Diabetes (2017-2018) - Pfizer : Diabetes (2017-2018) - Merck Sharp & Dohme : Heart failure (2017-2018) - Kowa : Lipidology (2017-2018) - Resverlogix : Lipidology. secondary prevention (2018)
Merkely Bela	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : ACS (2017) - Medtronic : CRT course (2017-2018) - Abbott : CRT/ICD (2017-2018) - Biotronik : ICD/CRT (2017-2018) - Astra Zeneca : HF (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : cardiac rhythm management (2017) - Medtronic : cardiac rhythm management (2017-2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Merkely Bela	- Boston Scientific : CRT (2017-2018)
Mueller Christian Eugen	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Servier : Antihypertensive (2017) - Siemens Healthcare : Diagnostics (2017) - Singulex : Diagnostics (2017) - Boehringer-Ingelheim : Antidiabetics (2017-2018) - Roche Diagnostics : Diagnostics (2017-2018) - Sanofi Aventis : Lipid lowering (2017-2018) - Indorsia : Antiplatelet therapy (2018) - Amgen : Lipid-lowering (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Beckman Coulter : Diagnostics (2017-2018) - OrthoClinical Diagnostics : Diagnostics (2017-2018) - Singulex : Diagnostics (2017-2018) - Abbott Laboratories : Diagnostics (2017-2018) - Roche Diagnostics : Diagnostics (2017-2018) - Siemens : Diagnostics (2017-2018) - Sphingotec : Diagnostics (2017-2018) - quidel : Diagnostics (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Petersen Steffen Erhard	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software (2017-2018) - Servier : Heart failure (2018) <p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - IMAGING (2017) - Healthcare - IMAGING - I have option for shares for Circle Cardiovascular Imaging Inc. (2018)
Petronio Anna Sonia	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : MitraClip (2017) - Boston Scientific : TAVI (2017) - Medtronic : TAVI (2017) - Boston Scientific : Percutaneous Aortic and Mitral treatment (2018) - Medtronic : Percutaneous Aortic and mitral treatment (2018) - Abbott : Percutaneous Mitral treatment (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : TAVI research (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Priori Silvia Giuliana	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Boston Scientific : Cardiac device (2017-2018)</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Audentes Rx : Gene therapy (2017-2018)</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY. - Takeda Pharmaceuticals : antiarrhythmic drugs (2017-2018)</p>
Richter Dimitrios	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Novo-Nordisk : diabetes (2017) - Novartis : hypertension (2017) - Galenica : Lipids (2017) - Teva Pharmaceutical Industries : lipids, hypertension (2017) - Edwards Lifesciences : aortic stenosis (2017-2018) - Menarini : CAD- hypertension (2017-2018) - Unipharma : hypertension-thrombosis (2017-2018) - Abbott : lipids (2017-2018) - Amgen : lipids (2017-2018)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Richter Dimitrios	<ul style="list-style-type: none"> - Sanofi Aventis : Lipids (2017-2018) - Lilly : Lipids (2017-2018) - Unilever : lipids (2017-2018) - Merck Sharp & Dohme : lipids (2017-2018) - Vianex : lipids (2017-2018) - Bayer Healthcare : Thrombosis (2017-2018) - Servier : LIPIDS (2018) - RAFARM : LIPIDS (2018) - ELPEN : LIPIDS-THROMBOSIS (2018) - Leo Pharma : THROMBOSIS (2018) - NovaGEM CYPRUS : THROMBOSIS (2018)
Roffi Marco	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : Stents (2017-2018) - Medtronic : Stents (2017-2018) - Biotronik : stents (2017-2018) - Terumo Inc : stents (2017-2018) - Abbott Vascular : stents (2017-2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Shlyakhto Evgeny	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Krka Pharma : Arterial Hypertension (2017-2018) - Novartis : Arterial Hypertension, Heart Failure (2017-2018) - Merck Sharp & Dohme : Atherosclerosis (2017-2018) - Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2017-2018) - Pfizer : General Cardiology (2017-2018)
Simpson Iain A	<p>Nothing to be declared (2018)</p> <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Member and Past President of the British Cardiovascular Society Member of the Management Board of the American College of Cardiology National Cardiovascular Data Registries (2017)
Sousa Uva Miguel	<p>Nothing to be declared (2017)</p> <p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : Surgical Valves (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Touyz Rhian	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : antihypertensive drugs (2017-2018) - Alnylam : antihypertensive drugs (2017-2018) <p>E - RESEARCH FUNDING (PERSONAL).</p> <ul style="list-style-type: none"> - British Heart Foundation : Hypertension research (2017-2018) - Medical Research Council, UK : Hypertension research (2017-2018) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - American Heart Association International Society of Hypertension British Irish Hypertension Society (2017-2018)
Windecker Stephan	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer AG : General Cardiology (2017) - Abbott : Invasive Cardiology (2017) - Boston Scientific : Invasive Cardiology (2017) - Edwards Lifesciences : invasive Cardiology (2017) - CSL Behring : Invasive Cardiology (2018) - Polares Medical : Invasive Cardiology (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - St. Jude Medical : General Cardiology (2017) - Amgen Inc. : General Cardiology (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> - Symetis SA : Invasive Cardiology (2017) - Biotronik : Invasive Cardiology (2017) - Terumo Inc : Invasive Cardiology (2017) - Abbott : General Cardiology (2017-2018) - Boston Scientific : General Cardiology (2017-2018) - Edwards Lifesciences : General Cardiology (2018) - Medtronic : General Cardiology (2018) - Biotronik : General Cardiology (2018) - Amgen Inc : General Cardiology (2018) - Bristol Myers Squibb : General Cardiology (2018) - Bayer AG : General Cardiology (2018) - Sinomed : General Cardiology (2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational and Entrepreneur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR (2017-2018)